• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Immunicon Corporation to Present at 2006 ASCO Annual Meeting; Posters Address Attributes of Circulating Tumor Cells

Posted on: Wednesday, 31 May 2006, 12:00 CDT

Immunicon Corporation (NASDAQ-NM:IMMC) will present three posters at the 42nd annual American Society of Clinical Oncology (ASCO), the premier educational and scientific event in the oncology community, June 2-6 at the Georgia World Congress Center in Atlanta, Georgia. The posters will address Immunicon's cellular analysis of circulating tumor cells (CTC) in patients with metastatic breast cancer; CTCs and circulating endothelial cells (CEC) in patients with metastatic colorectal cancer; and the assessment of CTCs in breast cancer patients undergoing neoadjuvant chemotherapy.

Poster Presentations will include: -- Sunday, June 4, 2006 General Poster Presentation -- "Circulating Tumor Cells (CTCs) in metastatic breast cancer: Biological value beyond tumor burden" presented by Massimo Cristofanilli, MD, 2:00 p.m.- 6:00 p.m., Abstract 615; Poster C8; Building B, Level 1, Hall B5 Poster Presentation -- "Circulating endothelial cells (CEC) and circulating tumor cells (CTC) in patients (pts) with metastatic colorectal cancer (mCRC)" presented by Steven J. Cohen, MD, 8:00 a.m.- 12:00 p.m.; Abstract 3531; Poster 19; Building B, Level 4, Room B 401, presentation 11:00- 11:12 a.m. -- Monday, June 5, 2006 General Poster Presentation -- "Assessment of circulating tumor cells in breast cancer patients undergoing neoadjuvant chemotherapy" presented by Jeffrey B. Smerage, MD, 8:00 a.m.-12:00 p.m.; Abstract 10079; Poster U1; Building B, Level 1, Hall B5

Following the conference, the Immunicon presentations will be posted on Immunicon's Web site at http://www.immunicon.com. The CellSearch(TM) System of assays, that identify, enumerate and characterize CTCs from a blood test, was developed by Immunicon and is marketed by Veridex, LLC, a Johnson & Johnson Company, and will be on display at the Veridex booth # 3150 during the meeting. For more about the 2006 ASCO Annual Meeting, visit http://www.asco.org/.

About Immunicon Corporation

Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products with an initial focus on cancer disease management. Immunicon has developed platform technologies for selection and analysis of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon's products and underlying technology platforms also have application in the clinical development of cancer drugs and in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. www.immunicon.com.

Forward-Looking Statements

The information contained in this press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as "hope,""may,""believe,""anticipate,""plan,""expect,""intend,""assume,""will" and similar expressions. Forward-looking statements contained in this press release include, among others, statements relating to Immunicon's anticipated net cash burn for 2006, Immunicon's funding strategy for commercialization activities and key product and clinical development programs and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date of this press release, reflect management's current expectations and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by Immunicon's forward-looking statements. These factors include, but are not limited to, risks and uncertainties associated with: Immunicon's dependence on Veridex, LLC, a Johnson & Johnson company, in the field of cancer cell analysis; Immunicon's capital and financing needs; research and development and clinical trial expenditures; commercialization of Immunicon's product candidates; Immunicon's ability to use licensed products and to obtain new licenses from third parties; Immunicon's ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to Immunicon's customers for Immunicon's products; compliance with applicable manufacturing standards; the ability to earn license and milestone payments under Immunicon's agreement with Veridex; retaining key management or scientific personnel; delays in the development of new products or to planned improvements to Immunicon's products; effectiveness of Immunicon's products compared to competitors' products; protection of Immunicon's intellectual property and other proprietary rights; conflicts with the intellectual property of third parties; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon's industry. These factors are discussed in more detail in Immunicon's filings with the Securities and Exchange Commission.

"Immunicon" and the Immunicon Corporation logo are registered trademarks of Immunicon Corporation. "CellSpotter,""CellTracks" and "AutoPrep" are registered trademarks of Immunivest Corporation, a wholly-owned subsidiary of Immunicon Corporation. CellTracks Analyzer II is a trademark of Immunivest Corporation. "CellSearch" is a trademark of Johnson & Johnson. All other trademarks or servicemarks appearing in this report are the property of their respective holders. ALL RIGHTS RESERVED.

Source: Business Wire

More News in this Category